Your browser doesn't support javascript.
loading
Compatibility of proton pump inhibitors in a preservative-free suspending vehicle.
Polonini, Hudson C; Silva, Sharlene L; Loures, Shirley; Almy, Rachel; Balland, Antoine; Brandão, Marcos Antônio F; Ferreira, Anderson O.
Afiliação
  • Polonini HC; Ortofarma-Quality Control Laboratories, Matias Barbosa, MG, Brazil.
  • Silva SL; Ortofarma-Quality Control Laboratories, Matias Barbosa, MG, Brazil.
  • Loures S; Ortofarma-Quality Control Laboratories, Matias Barbosa, MG, Brazil.
  • Almy R; Eurofins-Pharma Quality Control, Sainte Croix en Plaine, France.
  • Balland A; Eurofins-Pharma Quality Control, Sainte Croix en Plaine, France.
  • Brandão MAF; Ortofarma-Quality Control Laboratories, Matias Barbosa, MG, Brazil.
  • Ferreira AO; Ortofarma-Quality Control Laboratories, Matias Barbosa, MG, Brazil.
Eur J Hosp Pharm ; 25(3): 150-156, 2018 May.
Article em En | MEDLINE | ID: mdl-31157010
OBJECTIVES: To evaluate the microbiological and physicochemical compatibility of commonly used proton pump inhibitors (PPIs) esomeprazole, lansoprazole, omeprazole and pantoprazole compounded at a single concentration using SyrSpend SF Alka and stored at refrigerated temperatures (omeprazole was also stored at room temperature because it has the most widespread use). METHODS: Compatibility was assessed by measuring the per cent recovery at varying time points throughout a 90-day period. Quantification of the APIs was performed by a validated high performance liquid chromatography (HPLC-UV) method. This same assay was also used to determine the dosage content uniformity of the suspensions. Microbiological stability ('test in use') was assessed during 60 days and total aerobic microbial count (TAMC), total combined yeasts and moulds count (TYMC), detection of Escherichia coli and pH determination were performed. Antimicrobial effectiveness testing was determined following European Pharmacopoeia guidelines. RESULTS: Beyond-use dates of maximum 60 days for omeprazole (5 mg/mL), pantoprazole (3 mg/mL) and esomeprazole (3 mg/mL) were established. All suspensions that met the physicochemical criteria for stability also met the content uniformity criteria. The suspensions showed no antimicrobial efficiency against bacteria, yeasts and moulds as SyrSpend SF Alka is an unpreserved vehicle, but the 'test in use' showed that the suspensions can remain microbiologically stable for up to 60 days. CONCLUSIONS: SyrSpend SF Alka can be used to compound palatable (taste-masking properties) preservative-free oral suspensions with almost all commonly used PPIs.
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Eur J Hosp Pharm Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Eur J Hosp Pharm Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido